Results 241 to 250 of about 208,301 (303)

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Lung adenocarcinoma with KRAS-Q61H: clinicopathologic features, diagnostics, and the evolving treatment landscape. [PDF]

Front Oncol
Serafimidis I.
europepmc   +1 more source

Utility of Urinary Extracellular Vesicles for Colorectal Cancer: Comparison of DNA Quality and MRD Detection

Cancer Science, EarlyView.
Urinary EVs provide highly pure vesicles with superior DNA quality, making them a robust and completely non‐invasive source for molecular profiling. Urinary EV‐DNA–based MRD assessment shows significant prognostic value and may serve as a practical tool for postoperative monitoring and risk stratification in colorectal cancer.
Shintaro Kanaka, Takeshi Yamada, Fumi Asai, Yuta Shimizu, Kay Uehara, Akihisa Matsuda, Seiichi Shinji, Yasuyuki Yokoyama, Goro Takahashi, Takuma Iwai, Kohki Takeda, Sho Kuriyama, Toshimitsu Miyasaka, Koki Hayashi, Hiroshi Yoshida   +14 more
wiley   +1 more source

Genomic landscape of cholangiocarcinoma in India: ethnic variants and implications for targeted therapy. [PDF]

BMC Cancer
Suryavanshi M, Ostwal V, Javle M, Kumar M, Shetty O, Patil D, Sharma S, Limaye S, Patel A, Sirohi B, Bahl A, Rohtagi N.   +11 more
europepmc   +1 more source

Real-Time Visualization of Isoform-Specific RAF-KRAS Interactions in Living Cells Using FRET-BRET Hybrid Biosensors. [PDF]

Adv Sci (Weinh)
Go JM, Lee D, Kim M, Han K, Choi G, Song C, Ahn S, Lee Y, Lee J, Wang Y, Suh JS, Yun H, Kim TJ.   +12 more
europepmc   +1 more source

Tumor microenvironment-activated ferritin nanovector enables enhanced tumor delivery of KRAS^G12C inhibitors and degraders. [PDF]

Front Cell Dev Biol
Abbinantefina AP, Tito C, Masciarelli S, Tisci G, Sortoluzzi S, Ceci P, Falvo E, Exertier C, Troilo F, Petrozza V, Mai A, Rotili D, Fazi F, Colotti G.   +13 more
europepmc   +1 more source

RASGRP4 is a key factor in the KRAS activation mediated by SOS in tumor Y1 adrenocortical cell lines. [PDF]

Sci Rep
Montoni F, Wailemann RAM, Torres TEP, de Torres KAM, Fonseca CS, da Silva Reis M, Armelin HA.   +6 more
europepmc   +1 more source

Discovery of a novel <i>ITPR2::KRAS</i> fusion in large cell neuroendocrine lung cancer: a case report. [PDF]

Transl Lung Cancer Res
Patregnani AJ, Rouf R, Moline DR, von Dohlen G, Makovec A, Mroz P, Nelson AC, Hwang J, Kratzke RA.   +8 more
europepmc   +1 more source

Upregulation of itchy E3 ubiquitin protein ligase contributes to endometrial cancer through promoting forkhead box P1 degradation. [PDF]

Cytojournal
Zhang YH, Yu HY, Li CF, Li JC.
europepmc   +1 more source